Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of HKD 12.45 [2][9] Core Insights - The company reported a revenue of HKD 14.256 billion for 2025, representing a year-on-year increase of 20.8%. Adjusted net profit was HKD 1.530 billion, up 1.3% year-on-year, with an adjusted net profit margin of 10.7%, down 2.1 percentage points from the previous year [2][5] - The HNB (Heat-not-Burn) business is experiencing significant growth, with revenue surpassing HKD 12.5 billion, compared to HKD 2.2 billion in 2024. The new products have received positive consumer feedback, contributing to market share gains [9] - The vaporization business benefits from stricter industry regulations, enhancing the company's competitive advantage as a leading electronic vaporization device manufacturer [9] Financial Summary - For 2025, the company achieved total revenue of HKD 14.256 billion, with a projected growth rate of 20.8% for the year. The adjusted net profit is expected to be HKD 1.064 billion, with a decline of 18.4% year-on-year [5][10] - The company anticipates continued revenue growth, with projections of HKD 16.700 billion in 2026, HKD 19.977 billion in 2027, and HKD 23.011 billion in 2028 [5][10] - The adjusted net profit is forecasted to recover to HKD 1.265 billion in 2026, HKD 1.850 billion in 2027, and HKD 2.372 billion in 2028, with corresponding P/E ratios of 39, 27, and 21 respectively [5][10]

Investment Rating - The report maintains a "Recommended" rating for HASHKEY HLDGS, with a target price of HKD 8.66, compared to the current price of HKD 4.50 [3][8]. Core Insights - HASHKEY HLDGS reported total revenue of HKD 723 million for 2025, a slight increase of 0.3% year-on-year, while the annual loss narrowed by 8.8% to HKD 1.084 billion, with an adjusted loss of HKD 737 million, which represents a year-on-year increase of 35.1% [1][7]. - The company is positioned as a leading compliant virtual asset exchange in Hong Kong, with a focus on expanding its digital asset ecosystem through RWA (Real World Assets) and AI initiatives [7]. - The trading facilitation services generated revenue of HKD 523 million, accounting for 72.3% of total revenue, with a significant increase in trading volume in Hong Kong, which reached HKD 5.3 trillion, up 72.3% year-on-year [7]. - The on-chain services faced revenue pressure, with a 33.3% decline to HKD 83 million, primarily due to digital currency price fluctuations [7]. - Asset management services saw a revenue increase of 49.8% to HKD 117 million, with assets under management reaching HKD 7.2 billion by the end of 2025 [7]. - The company is leveraging AI to enhance operational efficiency and innovate business models, including exploring AI agent payment solutions [7]. Financial Summary - For 2025, HASHKEY HLDGS reported total revenue of HKD 723 million, with a gross profit of HKD 408 million, resulting in a gross margin of 56.5%, down from 73.9% in 2024 [7]. - The company forecasts revenues of HKD 1.089 billion, HKD 1.678 billion, and HKD 2.610 billion for 2026, 2027, and 2028, respectively, with expected growth rates of 51%, 54%, and 56% [9]. - The projected EPS for 2026, 2027, and 2028 are -0.25, -0.10, and -0.03 HKD, respectively [9].

Investment Rating - The report maintains a "Recommended" rating for HASHKEY HLDGS, with a target price of HKD 8.66, compared to the current price of HKD 4.50 [3][8]. Core Insights - HASHKEY HLDGS reported total revenue of HKD 723 million for 2025, a slight increase of 0.3% year-on-year, while the annual loss narrowed by 8.8% to HKD 1.084 billion, with an adjusted loss of HKD 737 million, which represents a year-on-year increase of 35.1% [1][7]. - The company is positioned as a leading compliant virtual asset exchange in Hong Kong, with a focus on expanding its digital asset ecosystem through RWA (Real World Assets) and AI initiatives [7]. - The trading facilitation services generated HKD 523 million in revenue, accounting for 72.3% of total revenue, with a significant increase in trading volume in Hong Kong, reaching HKD 5.3 trillion, a year-on-year growth of 72.3% [7]. - The company has established itself as the largest regional onshore digital trading platform in Asia, with a notable increase in institutional trading volume, which rose to HKD 4.31 trillion, a year-on-year increase of 57.5% [7]. - The asset management services segment saw a revenue increase of 49.8% year-on-year, reaching HKD 117 million, with total assets under management growing to HKD 7.2 billion by the end of 2025 [7]. Financial Summary - For 2025, HASHKEY HLDGS reported a gross profit of HKD 408 million, with a gross margin of 56.5%, down from 73.9% in 2024, primarily due to a decline in the gross margin of trading facilitation services [7]. - The company anticipates revenue growth of 51% in 2026, reaching HKD 1.089 billion, and expects to narrow its net loss to HKD 681 million [9]. - The projected earnings per share (EPS) for 2026 is expected to be -0.25 HKD, with further improvements anticipated in subsequent years [9].

- The report includes multiple quantitative models for A-share market timing, such as the "Volume Model," "Feature Institutional Model," "Feature Volume Model," "Smart Algorithm Model," and "Comprehensive Weapon V3 Model" [1][11][64] - The "Volume Model" is neutral in the short term, while the "Feature Institutional Model" is also neutral. The "Feature Volume Model" indicates bearish signals. The "Smart Algorithm Model" for CSI 300 and CSI 500 shows bearish signals [11][64] - For mid-term A-share market timing, the "Limit-Up and Limit-Down Model," "Up-Down Return Difference Model," and "Calendar Effect Model" are neutral [12][65] - The long-term "Momentum Model" is neutral [13][66] - The "Comprehensive Weapon V3 Model" and "Comprehensive Guozheng 2000 Model" indicate bearish signals for A-shares [14][67] - For Hong Kong stocks, the "Turnover-to-Volatility Model" shows bearish signals, while the "Up-Down Return Difference Model" and "Up-Down Return Similarity Model" are neutral [15][68] - Backtesting results for the "Double Bottom Pattern" show a weekly return of 3.17%, outperforming the Shanghai Composite Index by 4.26%. Since December 31, 2020, the cumulative return is 23.82%, exceeding the Shanghai Composite Index by 11.13% [43][47] - Backtesting results for the "Cup-and-Handle Pattern" show a weekly return of 1.07%, outperforming the Shanghai Composite Index by 2.17%. Since December 31, 2020, the cumulative return is 17.9%, exceeding the Shanghai Composite Index by 5.21% [43][44]

Investment Rating - The industry investment rating is "Recommendation" indicating an expected increase in the industry index by more than 5% over the next 3-6 months compared to the benchmark index [72]. Core Insights - The cultural and creative product market in China is steadily expanding, with the market size projected to grow from CNY 286.9 billion in 2019 to CNY 464.7 billion by 2029. Among materials, plastic resin is experiencing the fastest growth, while the metal cultural market is stable, with copper cultural products expected to reach a market size of CNY 1.6 billion in 2024, accounting for 6.3% of the metal cultural market [10][15]. - The industry exhibits a dual oligopoly structure, with the report's company, Copper Master, holding a significant online market share of 44.1% and a total market share of 35.0% in the copper cultural product market [22][23]. - Copper Master is expanding its direct sales network, with a focus on copper cultural products, which are the core of its offerings. The company plans to open approximately 70 new stores from 2026 to 2028, enhancing its offline presence [24][25]. Industry Overview Industry Scale - The cultural and creative product market is expected to grow significantly, with copper cultural products showing a compound annual growth rate (CAGR) of 7.3% from 2019 to 2024 [10][15]. - The demand for copper decorative items is strong, driven by gifting and decorative needs, with the market for copper figurines projected to be CNY 1.234 billion in 2024 [15][20]. Industry Structure - The copper cultural industry has around 1,000 participants, with a high concentration of market share among the top players. The top three companies hold a combined market share of 71.9% [22][23]. - Copper Master leads the market with a revenue of CNY 551.3 million in 2024, followed by Company A and Company B [23]. Company Performance - Copper Master reported a revenue of CNY 448 million in the first three quarters of 2025, reflecting an 11.2% year-on-year growth, with total sales exceeding 1.5 million units, a 35.1% increase [25][30]. - The company has maintained a gross margin of around 34.3% in 2025, although net profit margins have faced pressure due to increased expenses related to channel expansion and brand promotion [34][35].

Investment Rating - The report maintains a "Strong Buy" rating for several companies in the innovative drug sector, particularly highlighting the growth potential of companies like 加科思 (JAK-23E73) and others in the medical device and life sciences service sectors [10][15][17]. Core Insights - The innovative drug sector in China is experiencing high-quality growth, significantly outpacing global averages, with a focus on domestic companies gaining international market share [10]. - The medical device industry is seeing a recovery in bidding scales and a shift towards innovation, with companies like 迈瑞医疗 and 澳华内镜 being recommended for investment [15]. - The life sciences service sector is expected to rebound as demand increases, driven by both domestic and international markets, with companies like 百普赛斯 and 药康生物 highlighted for their growth potential [17]. Summary by Sections Market Review - The medical index increased by 1.49%, outperforming the沪深300 index by 2.9 percentage points, ranking 5th among 30 sectors [7]. - Top-performing stocks included 美诺华 and 万邦德, while stocks like 科源制药 and 长药退 faced significant declines [6][30]. Innovative Drugs - China has become a key player in global innovative drug development, with a notable increase in overseas licensing deals, suggesting a shift towards an "innovation-driven" revenue era [10]. - Recommended companies include 百利天恒, 百济神州, and 恒瑞医药, among others [10]. Medical Devices - The high-value consumables sector is seeing easing pressure from centralized procurement, with companies like 春立医疗 and 迈普医学 recommended for their growth potential [15]. - The medical equipment sector is expected to experience a recovery, with significant growth anticipated in 2025 [15]. Life Sciences Services - The sector is poised for a rebound, with increasing demand from both domestic and international markets, and companies like 百普赛斯 and 药康生物 are expected to benefit [17]. Traditional Chinese Medicine - The report emphasizes the importance of basic drugs and state-owned enterprise reforms, recommending companies like 昆药集团 and 康缘药业 for their growth potential [21]. Pharmacy Sector - The pharmacy sector is expected to benefit from the acceleration of prescription outflow and an improved competitive landscape, with companies like 老百姓 and 益丰药房 highlighted for investment [18]. Medical Services - The report suggests a positive outlook for private medical services, particularly for companies like 固生堂 and 爱尔眼科, due to market improvements and expanding insurance coverage [20].

证 券 研 究 报 告 中国金茂（00817.HK）2025 年业绩点评 推荐（维持） 开发业务毛利率改善，积极拿地换仓 目标价：1.8 港元 事项： 2025 年公司实现营业收入 593.7 亿元，同比上升 0.5%；股东应占利润 12.53 亿 元（含永续债利息），同比上升 18%。 评论： 风险提示：房地产市场超预期下行，拿地兑现度不及预期。 [主要财务指标 Indicator_FinchinaSimpleHK] | | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 59,371 | 59,497 | 62,882 | 64,725 | | 同比增速(%) | 0.5% | 0.2% | 5.7% | 2.9% | | 归属普通股东净利润(百万元) | 592 | 992 | 1,209 | 1,296 | | 同比增速(%) | -15.6% | 67.6% | 21.9% | 7.2% | | 每股盈利(元) | 0.04 | 0.07 | 0.09 | 0.10 | | 市盈率(倍) | ...

Investment Rating - The report maintains a "Strong Buy" rating for Smoore International (06969.HK) with a target price of HKD 12.45 [2][9] Core Insights - In 2025, Smoore International achieved revenue of HKD 14.256 billion, representing a year-on-year increase of 20.8%. The adjusted net profit was HKD 1.530 billion, up 1.3% year-on-year, with an adjusted net profit margin of 10.7%, down 2.1 percentage points from the previous year [2][5] - The HNB (Heat-not-Burn) business is expanding, contributing significantly to revenue growth, with HNB revenue surpassing HKD 1.25 billion in 2025, compared to HKD 220 million in 2024. The company is expected to continue supporting strategic customers in promoting HNB products globally [9][10] - The vaping business benefits from stricter industry regulations, enhancing the market position of compliant companies like Smoore. The ODM (Original Design Manufacturer) business generated revenue of HKD 11.34 billion, up 21.7% year-on-year, with notable growth in Europe and the U.S. markets [9][10] Financial Summary - Total revenue for 2025 is projected at HKD 14.256 billion, with expected growth rates of 17.1%, 19.6%, and 15.2% for 2026, 2027, and 2028 respectively [5][10] - The adjusted net profit for 2025 is estimated at HKD 1.064 billion, with a projected growth rate of -18.4% for 2026, followed by 18.9% and 46.2% for 2027 and 2028 respectively [5][10] - The company’s gross margin for 2025 is reported at 34.1%, down 3.3 percentage points year-on-year, primarily due to a higher proportion of lower-margin products [9][10]

Investment Rating - The report maintains a "Strong Buy" rating for several companies in the innovative drug sector, particularly focusing on those with promising pipelines and market potential [14]. Core Insights - The innovative drug sector in China is experiencing high-quality growth in research and development, significantly outpacing global averages. This trend positions China as a key player in the global innovative drug market [10]. - The medical device sector is seeing a recovery in bidding scales and a shift towards innovation, with companies like Mindray Medical and Aohua Endoscopy being highlighted for their growth potential [15]. - The life sciences service sector is expected to rebound as demand increases, driven by both domestic and international markets, with companies like BGI Genomics and Nanwei Technology being recommended for investment [17]. - The pharmacy sector is poised for growth due to the acceleration of prescription outflow and an improving competitive landscape, with companies like YaoBaiYao and YiFeng Pharmacy being noted as key players [18]. Summary by Sections Market Review - The medical index rose by 1.49%, outperforming the CSI 300 index by 2.9 percentage points, ranking fifth among 30 sectors [7]. - Top-performing stocks included Meinuohua and Wanbangde, while stocks like Keyuan Pharmaceutical and Changyao Tui faced significant declines [30]. Innovative Drugs - The report emphasizes the importance of innovative drugs, with a focus on companies like BeiGene and Hengrui Medicine, which are expected to benefit from global market expansion [10][14]. - The collaboration between companies like JAK-23E73 and AstraZeneca is highlighted as a significant advancement in the innovative drug pipeline [14]. Medical Devices - The report notes a recovery in the medical device sector, with a focus on high-value consumables and the internationalization of domestic companies [15]. - Companies such as Mindray Medical and Aohua Endoscopy are recommended for their innovative products and growth potential in both domestic and international markets [15]. Life Sciences Services - The life sciences service sector is expected to see a recovery in demand, with companies like BGI Genomics and Bioplus being highlighted for their growth potential [17]. - The report indicates that the sector's profitability is expected to improve as revenue growth resumes [17]. Pharmacy Sector - The pharmacy sector is expected to benefit from the acceleration of prescription outflow and an improved competitive landscape, with companies like YaoBaiYao and YiFeng Pharmacy being recommended for investment [18]. - The report suggests that the integration of online and offline pharmacy services will enhance competitiveness [18]. Traditional Chinese Medicine - The report highlights the potential for growth in traditional Chinese medicine, particularly in basic drug categories and state-owned enterprise reforms [21]. - Companies like Kunming Pharmaceutical and Kangyuan Pharmaceutical are recommended for their strong market positions [21]. Medical Services - The report suggests that the medical services sector will benefit from anti-corruption measures and the expansion of private healthcare, with companies like Gushengtang and Aier Eye Hospital being noted for their growth potential [20]. Blood Products - The report indicates that the blood products sector is expected to see growth due to relaxed approval processes and increasing demand, with companies like Tiantan Biological Products being highlighted [12].

证 券 研 究 报 告 新华保险（601336）2025 年报点评 推荐（维持） 事项： 2025 年公司实现归母净利润 363 亿元，同比+38.3%；NBV 同比+57.4%至 98 亿元；净/总/综合投资收益率分别为 2.8%/6.6%/5%，同比-0.4pct/+0.8pct/-3.5pct。 拟派发末期股息每股 2.06 元（含税）。 评论： [ReportFinancialIndex] 主要财务指标 | | 2025 | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 157745 | 138676 | 137623 | 146025 | | 同比增速(%) | 19.0 | -12.1 | -0.8 | 6.1 | | 归母净利润(百万) | 36284 | 37246 | 38488 | 40558 | | 同比增速(%) | 38.3 | 2.7 | 3.3 | 5.4 | | 每股盈利(元) | 11.6 | 11.9 | 12.3 | 13.0 | | 市盈率(倍) | 5.4 | 5.3 | 5 ...